Elizabeth C. Saunders

Elizabeth C. Saunders

Auto-generated profile, based on publicly available information

Elizabeth C. Saunders

Center for Technology and Behavioral Health, Geisel School of Medicine at Dartmouth College, Lebanon, NH, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2020 in BMC Pregnancy and Childbirth
Verified
Journal Article
Open access
PDF file
DGDaisy J. Goodman
Daisy J. Goodman
ESElizabeth C. Saunders
Elizabeth C. Saunders
KWKristina B. Wolff
Kristina B. Wolff
Background: Opioid use disorder (OUD) is associated with substantial morbidity and mortality for women, especially during the perinatal period. Opioid overdose has become a significant cause of maternal death in the United States, with rates highest in the immediate postpartum year. While pregnancy is a time of high motivation for healthcare engagement, unique challenges exist for pregnant women with OUD seeking both substance use treatment and maternity care, including managing change after birth. How women successfully navigate these barriers, engage in treatment, and abstain from substance use during pregnancy and postpartum is poorly understood. The aim of this study is to explore the experiences of postpartum women with OUD who successfully engaged in both substance use treatment and maternity care during pregnancy, to understand factors contributing to their ability to access care and social support. Methods: We conducted semi-structured, in-depth interviews with postpartum women in sustained recovery (n = 10) engaged in a substance use treatment program in northern New England. Interviews were analyzed using grounded theory methodology. Results: Despite multiple barriers, women identified pregnancy as a change point from which they were able to develop self-efficacy and exercise agency in seeking care. A shift in internal motivation enabled women to disclose need for OUD treatment to maternity care providers, a profoundly significant moment. Concurrently, women developed a new capacity for self-care, demonstrated through managing relationships with providers and family members, and overcoming logistical challenges which had previously seemed overwhelming. This transformation was also expressed in making decisions based on pregnancy risk, engaging with and caring for others, and providing peer support. Women developed resilience through the interaction of inner motivation and their ability to positively utilize or transform external factors. Conclusions: Complex interactions occurred between individual-level changes in treatment motivation due to pregnancy, emerging self-efficacy in accessing resources, and engagement with clinicians and peers. This transformative process was identified by women as a key factor in entering recovery during pregnancy and sustaining it postpartum. Clinicians and policymakers should target the provision of services which promote resilience in pregnant women with OUD.

1 December 2019 in International Journal of Drug Policy
Verified
Journal Article
Closed access
SBSarah Bessen
Sarah Bessen
SMStephen A. Metcalf
Stephen A. Metcalf
ESElizabeth C. Saunders
Elizabeth C. Saunders
SMSarah K. Moore
Sarah K. Moore
AMAndrea Meier
Andrea Meier
LMLisa A. Marsch
Lisa A. Marsch

14 August 2019 in Journal of General Internal Medicine
Verified
Journal Article
Open access
PDF file
ESElizabeth C. Saunders
Elizabeth C. Saunders
SMSarah K. Moore
Sarah K. Moore
TGTrip Gardner
Trip Gardner
SFSarah Farkas
Sarah Farkas
LMLisa A. Marsch
Lisa A. Marsch
JMJennifer McNeely
Jennifer McNeely
Background Substance use frequently goes undetected in primary care. Though barriers to implementing systematic screening for alcohol and drug use have been examined in urban settings, less is known about screening in rural primary care. Objective To identify current screening practices, barriers, facilitators, and recommendations for the implementation of substance use screening in rural federally qualified health centers (FQHCs). Design As part of a multi-phase study implementing electronic health record–integrated screening, focus groups (n = 60: all stakeholder groups) and individual interviews (n = 10 primary care providers (PCPs)) were conducted. Participants Three stakeholder groups (PCPs, medical assistants (MAs), and patients) at three rural FQHCs in Maine. Approach Focus groups and interviews were recorded, transcribed, and content analyzed. Themes surrounding current substance use screening practices, barriers to screening, and recommendations for implementation were identified and organized by the Knowledge to Action (KTA) Framework. Key Results Identifying the problem: Stakeholders unanimously agreed that screening is important, and that universal screening is preferred to targeted approaches. Adapting to the local context: PCPs and MAs agreed that screening should be done annually. Views were mixed regarding the delivery of screening; patients preferred self-administered, tablet-based screening, while MAs and PCPs were divided between self-administered and face-to-face approaches. Assessing barriers: For patients, barriers to screening centered around a perceived lack of rapport with providers, which contributed to concerns about trust, judgment, and privacy. For PCPs and MAs, barriers included lack of comfort, training, and preparedness to address screening results and offer treatment. Conclusions Though stakeholders agree on the importance of implementing universal screening, concerns about the patient-provider relationship, the consequences of disclosure, and privacy appear heightened by the rural context. Findings highlight that strong relationships with providers are critical for patients, while in-clinic resources and training are needed to increase provider comfort and preparedness to address substance use.

21 January 2020 in Journal of Substance Abuse Treatment
Verified
Journal Article
Closed access
ESElizabeth C. Saunders
Elizabeth C. Saunders
SMSarah K. Moore
Sarah K. Moore
OWOlivia Walsh
Olivia Walsh
SMStephen A. Metcalf
Stephen A. Metcalf
ABAlan J. Budney
Alan J. Budney
LMLisa A. Marsch
Lisa A. Marsch

1 January 2022 in American Journal of Obstetrics & Gynecology MFM
Verified
Journal Article
Closed access
DGDaisy J. Goodman
Daisy J. Goodman
ESElizabeth C. Saunders
Elizabeth C. Saunders
JFJulia R. Frew
Julia R. Frew
CACybele Arsan
Cybele Arsan
HXHaiyi Xie
Haiyi Xie
MBMary F. Brunette
Mary F. Brunette

1 September 2019 in Contemporary Clinical Trials Communications
Verified
Journal Article
Open access
AHAugust F. Holtyn
August F. Holtyn
EBEugene Bosworth
Eugene Bosworth
LMLisa A. Marsch
Lisa A. Marsch
BMBethany McLeman
Bethany McLeman
AMAndrea Meier
Andrea Meier
UGUdi E. Ghitza
Udi E. Ghitza
Cocaine use in clinical trials is often measured via self-report, which can be inaccurate, or urine drug screens, which can be intrusive and burdensome. Devices that can automatically detect cocaine use and can be worn conveniently in daily life may provide several benefits. AutoSense is a wearable, physiological-monitoring suite that can detect cocaine use, but it may be limited as a method for monitoring cocaine use because it requires wearing a chestband with electrodes. This paper describes the design, rationale, and methodology of a project that seeks to build upon and extend previous work in the development of methods to detect cocaine use via wearable, unobtrusive mobile sensor technologies. To this end, a wrist-worn sensor suite (i.e., MotionSense HRV) will be developed and evaluated. Participants who use cocaine (N = 25) will be asked to wear MotionSense HRV and AutoSense for two weeks during waking hours. Drug use will be assessed via thrice-weekly urine drug screens and self-reports, and will be used to isolate periods of cocaine use that will be differentiated from other drug use. The present study will provide information on the feasibility and acceptability of using a wrist-worn device to detect cocaine use.